The Cell-Free Fetal DNA  Testing Market is one of the most dynamic segments in the prenatal diagnostics industry, offering a non-invasive approach to early detection of chromosomal abnormalities such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). This technology, known as non-invasive prenatal testing (NIPT), analyzes fetal DNA...